

Qiagen makes changes in supervisory board

30 April 2013 | News | By BioSpectrum Bureau



Singapore: Qiagen is going to make changes in the membership of the supervisory board that will be put forward for approval by shareholders at the next annual general meeting scheduled for June 26, 2013.

The proposals for the composition of the supervisory board, who are elected to one-year terms, were made by the selection and appointment committee and recommended for shareholder approval by a joint meeting of the supervisory board and the managing board.

Prof Dr Detlev H. Riesner, co-founder of Qiagen and chairman of the supervisory board, decided to stand for re-election for the last time at the annual general meeting in June 2013. The joint meeting has discussed a proposal for Dr Werner Brandt to succeed Professor Riesner as chairman of the supervisory board in 2014 after he retires from his current position as a member of the executive board of SAP.

Dr Brandt, who has more than 30 years of leadership experience in the healthcare and IT industries, joined the supervisory board in 2007, and was also appointed in the same year as chairman of the audit committee.

The two new members who have been proposed for election to the supervisory board are Mr Stéphane Bancel, president and founding CEO, Moderna Therapeutics, and Mr Lawrence A Rosen, member of the board of management and chief financial officer of Deutsche Post DHL.